{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-008745","form_type":"8-K","ticker":null,"cik":"0000316253","company_name":"ENZO BIOCHEM INC","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.548091+00:00","generated_at":"2026-06-06T11:45:07.347018+00:00","sec_items":["5.02","5.07","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enzo Biochem names permanent CEO and CFO; shareholders reject say-on-pay","bullets":["Kara Cannon appointed permanent CEO (was interim since Sept 2023); Patricia Eckert appointed permanent CFO.","Shareholders elected directors Pully, Radoff, Tagliaferri, Cannon; Radoff and Tagliaferri had narrow margins.","Non-binding advisory vote on executive compensation rejected: 13.9M for vs 17.3M against.","Shareholders ratified EisnerAmper as independent auditor for FY2024 ending July 31, 2024.","44.4M shares (87.94%) represented at meeting; quorum present."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-008745","json":"https://secwatch.observer/filing/0001213900-24-008745.json","markdown":"https://secwatch.observer/filing/0001213900-24-008745.md","text":"https://secwatch.observer/filing/0001213900-24-008745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/316253/000121390024008745/0001213900-24-008745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/316253/000121390024008745/ea192624-8k_enzobiochem.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:45:07.347018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4213a01c1b","claim":"Kara Cannon was appointed as Chief Executive Officer at ENZO BIOCHEM INC.","evidence_excerpt":"On January 31, 2024, the board of directors (the “Board”) of Enzo Biochem, Inc. (the “Company”) appointed Kara Cannon to serve as the Chief Executive Officer of the Company and Patricia Eckert, CPA, to serve as the Chief Financial Officer of the Company, in each case, until her successor is duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390024008745/0001213900-24-008745-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"94ea023505","claim":"Patricia Eckert was appointed as Chief Financial Officer at ENZO BIOCHEM INC.","evidence_excerpt":"On January 31, 2024, the board of directors (the “Board”) of Enzo Biochem, Inc. (the “Company”) appointed Kara Cannon to serve as the Chief Executive Officer of the Company and Patricia Eckert, CPA, to serve as the Chief Financial Officer of the Company, in each case, until her successor is duly elected and qualified.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390024008745/0001213900-24-008745-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b189ebc3f653543587c6bb65ca8da7044dd0b8e6","claim":"ENZO BIOCHEM INC shareholders rejected Approval, by a nonbinding advisory vote, of the compensation of the Company's named executive officers.","evidence_excerpt":"The shareholders of the Company did not approve, by a nonbinding advisory vote, the compensation of the Company's named executive officers, as set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390024008745/0001213900-24-008745-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"failed"}],"fact_type":"shareholder_vote"},{"claim_id":"d305fdb22ad6affd1e69dc18d884ac359079eaa4","claim":"ENZO BIOCHEM INC shareholders approved Ratification of the Company's appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending July 31, 2024 at the 2024-07-31 meeting.","evidence_excerpt":"The shareholders of the Company ratified the Company's appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the Company's fiscal year ending July 31, 2024, as set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390024008745/0001213900-24-008745-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-07-31"}],"fact_type":"shareholder_vote"},{"claim_id":"ee484849f4cec3142d1c88c373874d7f94b24ddd","claim":"ENZO BIOCHEM INC shareholders approved Election of Steven J. Pully, Bradley L. Radoff, Mary Tagliaferri, M.D., and Kara Cannon to the Board.","evidence_excerpt":"The shareholders of the Company elected each of Steven J. Pully, Bradley L. Radoff, Mary Tagliaferri, M.D., and Kara Cannon to serve on the Board for a term ending as of the Company's 2024 Annual Meeting of Shareholders, and until each such director's successor is elected and qualified, as set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390024008745/0001213900-24-008745-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}